{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:16:47Z","timestamp":1778721407236,"version":"3.51.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08026-9","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:13:23Z","timestamp":1775207603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An international, double-blind, randomized, placebo-controlled clinical trial of adjunctive trimetazidine to treat people with bipolar depression (the TIDE trial) protocol"],"prefix":"10.1186","volume":"26","author":[{"given":"Jee Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Hui J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi V.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourav","family":"Khanra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam Sundar","family":"Arumugham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesan","family":"Venkatasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monojit","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Arasappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie M.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Panizzutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyna","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varshitha","family":"Tholasappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devangi","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin Tudur","family":"Sadashiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhakar","family":"Dombale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Mohebbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Pacchiarotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreekantiah","family":"Umesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Walder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi","family":"Yatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishant","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. C. Janardhan","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muralidharan","family":"Kesavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"8026_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jpsychires.2020.03.015","volume":"125","author":"H He","year":"2020","unstructured":"He H, Hu C, Ren Z, Bai L, Gao F, Lyu J. Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: Results from the global burden of Disease Study 2017. J Psychiatr Res. 2020;125:96\u2013105.","journal-title":"J Psychiatr Res"},{"issue":"10","key":"8026_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s40265-023-01872-x","volume":"83","author":"K Keramatian","year":"2023","unstructured":"Keramatian K, Chakrabarty T, DuBois A, Saraf G, Yatham LN. New Pharmacologic Approaches to the Treatment of Bipolar Depression. Drugs. 2023;83(10):843\u201363.","journal-title":"Drugs"},{"issue":"6","key":"8026_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","volume":"59","author":"LL Judd","year":"2002","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 2","key":"8026_CR4","first-page":"53","volume":"60","author":"SG Simpson","year":"1999","unstructured":"Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry. 1999;60(Suppl 2):53\u20136. discussion 75\u2009\u2013\u200956.","journal-title":"J Clin Psychiatry"},{"issue":"10027","key":"8026_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","volume":"387","author":"I Grande","year":"2016","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561\u201372.","journal-title":"Lancet"},{"key":"8026_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jad.2015.02.011","volume":"178","author":"A Forte","year":"2015","unstructured":"Forte A, Baldessarini RJ, Tondo L, V\u00e1zquez GH, Pompili M, Girardi P. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015;178:71\u20138.","journal-title":"J Affect Disord"},{"issue":"4","key":"8026_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/inm.12482","volume":"27","author":"M Banfield","year":"2018","unstructured":"Banfield M, Randall R, O\u2019Brien M, Hope S, Gulliver A, Forbes O, Morse AR, Griffiths K. Lived experience researchers partnering with consumers and carers to improve mental health research: Reflections from an Australian initiative. Int J Ment Health Nurs. 2018;27(4):1219\u201329.","journal-title":"Int J Ment Health Nurs"},{"issue":"7","key":"8026_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S2215-0366(25)00066-5","volume":"12","author":"M Berk","year":"2025","unstructured":"Berk M, Kim JH, Williams LJ, Liu ZSJ, Siskind D, Panizzutti B, Yung AR, Walder K. A novel discovery platform for targeted drug repurposing: application for psychiatric disorders. Lancet Psychiatry. 2025;12(7):535\u201342.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"8026_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12888-018-1622-1","volume":"18","author":"L Ohlund","year":"2018","unstructured":"Ohlund L, Ott M, Oja S, Bergqvist M, Lundqvist R, Sandlund M, Salander Renberg E, Werneke U. Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study. BMC Psychiatry. 2018;18(1):37.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"8026_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12888-020-02767-x","volume":"20","author":"L Bessonova","year":"2020","unstructured":"Bessonova L, Velligan DI, Weiden PJ, O\u2019Sullivan AK, Yarlas A, Bayliss M, Baranwal N, Rychlec K, Carpenter-Conlin J, Doane MJ, et al. Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey. BMC Psychiatry. 2020;20(1):354.","journal-title":"BMC Psychiatry"},{"key":"8026_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jad.2019.08.008","volume":"261","author":"A Pigoni","year":"2020","unstructured":"Pigoni A, Mandolini GM, Delvecchio G, Bressi C, Soares JC, Brambilla P. A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review: Special Section on Translational and Neuroscience Studies in Affective Disorders Section Editor, Maria Nobile MD, PhD. J Affect Disord. 2020;261:277\u201381.","journal-title":"J Affect Disord"},{"key":"8026_CR12","doi-asserted-by":"crossref","unstructured":"Kim JH, Walder K, Panizzutti B, Williams LJ, Berk M. The Drug Discovery Drought in Bipolar Disorder: Barriers and Solutions. Biol Psychiatry; 2025.","DOI":"10.1016\/j.biopsych.2025.02.006"},{"issue":"7","key":"8026_CR13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.cell.2018.05.046","volume":"173","author":"DM Ruderfer","year":"2018","unstructured":"Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ruderfer DM, Ripke S, McQuillin A, Boocock J, Stahl EA, Pavlides JMW, Mullins N, Charney AW, Ori APS, et al. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell. 2018;173(7):1705\u2013e17151716.","journal-title":"Cell"},{"issue":"3","key":"8026_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.mehy.2014.06.017","volume":"83","author":"JC Narayanaswamy","year":"2014","unstructured":"Narayanaswamy JC, Moily N, Kubendran S, Reddy YC, Jain S. Does latitude as a zeitgeber affect the course of bipolar affective disorder? Med Hypotheses. 2014;83(3):387\u201390.","journal-title":"Med Hypotheses"},{"issue":"10265","key":"8026_CR15","first-page":"1841","volume":"396","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Berk M, Brietzke E, Goldstein BI, Lopez-Jaramillo C, Kessing LV, Malhi GS, Nierenberg AA, Rosenblat JD, Majeed A, et al. Bipolar disorders Lancet. 2020;396(10265):1841\u201356.","journal-title":"Bipolar disorders Lancet"},{"issue":"2","key":"8026_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41380-018-0044-2","volume":"24","author":"RJ Baldessarini","year":"2019","unstructured":"Baldessarini RJ, Tondo L, Vazquez GH. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry. 2019;24(2):198\u2013217.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"8026_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41380-020-0831-4","volume":"26","author":"SJ Haggarty","year":"2021","unstructured":"Haggarty SJ, Karmacharya R, Perlis RH. Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry. 2021;26(1):168\u201385.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"8026_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1152\/physiolgenomics.00115.2010","volume":"43","author":"N Konstantopoulos","year":"2011","unstructured":"Konstantopoulos N, Foletta VC, Segal DH, Shields KA, Sanigorski A, Windmill K, Swinton C, Connor T, Wanyonyi S, Dyer TD, et al. A gene expression signature for insulin resistance. Physiol Genom. 2011;43(3):110\u201320.","journal-title":"Physiol Genom"},{"issue":"11","key":"8026_CR19","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.2337\/dc14-1038","volume":"37","author":"RW Simpson","year":"2014","unstructured":"Simpson RW, Nicholson GC, Proietto J, Sarah A, Sanders KM, Phillips G, Chambers J, MacGinley R, Orford N, Walder K, et al. Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study: Table 1. Diabetes Care. 2014;37(11):3121\u20133.","journal-title":"Diabetes Care"},{"issue":"8","key":"8026_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bdi.13319","volume":"25","author":"CC Bortolasci","year":"2023","unstructured":"Bortolasci CC, Kidnapillai S, Spolding B, Truong TTT, Connor T, Swinton C, Panizzutti B, Liu ZSJ, Sanigorski A, Dean OM, et al. Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression. Bipolar Disord. 2023;25(8):661\u201370.","journal-title":"Bipolar Disord"},{"issue":"8","key":"8026_CR21","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1038\/s41380-023-02134-8","volume":"28","author":"S Khanra","year":"2023","unstructured":"Khanra S, Reddy P, Gimenez-Palomo A, Park CHJ, Panizzutti B, McCallum M, Arumugham SS, Umesh S, Debnath M, Das B, et al. Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine. Mol Psychiatry. 2023;28(8):3231\u201342.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"8026_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijcard.2012.09.123","volume":"163","author":"G Fragasso","year":"2013","unstructured":"Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L, Calori G, Kang SM, Sahakyan L, Sanosyan A, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163(3):320\u20135.","journal-title":"Int J Cardiol"},{"key":"8026_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1527-3466.1988.tb00381.x","volume":"6","author":"C Harpey","year":"1989","unstructured":"Harpey C, Clauser P, Labrid C, Freyria J, Poirier J. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev. 1989;6:292\u2013312.","journal-title":"Cardiovasc Drug Rev"},{"issue":"4","key":"8026_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/0003319718780551","volume":"70","author":"MS Kallistratos","year":"2019","unstructured":"Kallistratos MS, Poulimenos LE, Giannitsi S, Tsinivizov P, Manolis AJ. Trimetazidine in the Prevention of Tissue Ischemic Conditions. Angiology. 2019;70(4):291\u20138.","journal-title":"Angiology"},{"issue":"12","key":"8026_CR25","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.108.778019","volume":"118","author":"H Tuunanen","year":"2008","unstructured":"Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118(12):1250\u20138.","journal-title":"Circulation"},{"issue":"2","key":"8026_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1472-8206.2003.00154.x","volume":"17","author":"WC Stanley","year":"2003","unstructured":"Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol. 2003;17(2):133\u201345.","journal-title":"Fundam Clin Pharmacol"},{"key":"8026_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ijcard.2015.11.060","volume":"203","author":"YM Lopatin","year":"2016","unstructured":"Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH, Vinereanu D, Hamid MA, Jourdain P, Ponikowski P. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. Int J Cardiol. 2016;203:909\u201315.","journal-title":"Int J Cardiol"},{"issue":"5","key":"8026_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","volume":"86","author":"PF Kantor","year":"2000","unstructured":"Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580\u20138.","journal-title":"Circ Res"},{"issue":"1","key":"8026_CR29","doi-asserted-by":"publisher","first-page":"19116","DOI":"10.1038\/s41598-021-98771-6","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang W, You B, Qi D, Qiu L, Ripley-Gonzalez JW, Zheng F, Fu S, Li C, Dun Y, Liu S. Trimetazidine and exercise provide comparable improvements to high fat diet-induced muscle dysfunction through enhancement of mitochondrial quality control. Sci Rep. 2021;11(1):19116.","journal-title":"Sci Rep"},{"issue":"11","key":"8026_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.lfs.2012.03.015","volume":"92","author":"P Zhao","year":"2013","unstructured":"Zhao P, Zhang J, Yin XG, Maharaj P, Narraindoo S, Cui LQ, Tang YS. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 2013;92(11):633\u20138.","journal-title":"Life Sci"},{"issue":"1","key":"8026_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/wps.21266","volume":"24","author":"M Berk","year":"2025","unstructured":"Berk M, Walder K, Kim JH. Past, present and future of research on brain energy metabolism in bipolar disorder. World Psychiatry. 2025;24(1):47\u20139.","journal-title":"World Psychiatry"},{"issue":"3 Pt 1","key":"8026_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1034\/j.1399-5618.2000.020305.x","volume":"2","author":"T Kato","year":"2000","unstructured":"Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000;2(3 Pt 1):180\u201390.","journal-title":"Bipolar Disord"},{"issue":"Pt A","key":"8026_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2017.01.014","volume":"74","author":"G Morris","year":"2017","unstructured":"Morris G, Walder K, McGee SL, Dean OM, Tye SJ, Maes M, Berk M. A model of the mitochondrial basis of bipolar disorder. Neurosci Biobehav Rev. 2017;74(Pt A):1\u201320.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"8026_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2174\/1389557515666150324122026","volume":"15","author":"E Callaly","year":"2015","unstructured":"Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem. 2015;15(5):355\u201365.","journal-title":"Mini Rev Med Chem"},{"issue":"7","key":"8026_CR35","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1007\/s11033-020-05590-5","volume":"47","author":"G Morris","year":"2020","unstructured":"Morris G, Walder KR, Berk M, Marx W, Walker AJ, Maes M, Puri BK. The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it? Mol Biol Rep. 2020;47(7):5587\u2013620.","journal-title":"Mol Biol Rep"},{"key":"8026_CR36","doi-asserted-by":"publisher","first-page":"546801","DOI":"10.3389\/fpsyt.2021.546801","volume":"12","author":"A Gimenez-Palomo","year":"2021","unstructured":"Gimenez-Palomo A, Dodd S, Anmella G, Carvalho AF, Scaini G, Quevedo J, Pacchiarotti I, Vieta E, Berk M. The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment. Front Psychiatry. 2021;12:546801.","journal-title":"Front Psychiatry"},{"issue":"8","key":"8026_CR37","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1006\/jmcc.1994.1116","volume":"26","author":"E Fantini","year":"1994","unstructured":"Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994;26(8):949\u201358.","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"8026_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.metabol.2015.10.022","volume":"65","author":"Z Liu","year":"2016","unstructured":"Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, et al. The protective effect of trimetazidine on myocardial ischemia\/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism. 2016;65(3):122\u201330.","journal-title":"Metabolism"},{"issue":"3","key":"8026_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bcp.2014.07.022","volume":"91","author":"J Kuzmicic","year":"2014","unstructured":"Kuzmicic J, Parra V, Verdejo HE, Lopez-Crisosto C, Chiong M, Garcia L, Jensen MD, Bernlohr DA, Castro PF, Lavandero S. Trimetazidine prevents palmitate-induced mitochondrial fission and dysfunction in cultured cardiomyocytes. Biochem Pharmacol. 2014;91(3):323\u201336.","journal-title":"Biochem Pharmacol"},{"key":"8026_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.psychres.2018.03.089","volume":"264","author":"SS Valvassori","year":"2018","unstructured":"Valvassori SS, Bavaresco DV, Feier G, Cechinel-Recco K, Steckert AV, Varela RB, Borges C, Carvalho-Silva M, Gomes LM, Streck EL, et al. Increased oxidative stress in the mitochondria isolated from lymphocytes of bipolar disorder patients during depressive episodes. Psychiatry Res. 2018;264:192\u2013201.","journal-title":"Psychiatry Res"},{"issue":"7","key":"8026_CR41","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1515\/cclm-2013-0978","volume":"52","author":"P Moutsatsou","year":"2014","unstructured":"Moutsatsou P, Tsoporis JN, Salpeas V, Bei E, Alevizos B, Anagnostara C, Izhar S, Proteau G, Rizos E, Hatziagelaki E, et al. Peripheral blood lymphocytes from patients with bipolar disorder demonstrate apoptosis and differential regulation of advanced glycation end products and S100B. Clin Chem Lab Med. 2014;52(7):999\u20131007.","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"8026_CR42","doi-asserted-by":"publisher","first-page":"e1111","DOI":"10.1038\/tp.2017.83","volume":"7","author":"G Scaini","year":"2017","unstructured":"Scaini G, Fries GR, Valvassori SS, Zeni CP, Zunta-Soares G, Berk M, Soares JC, Quevedo J. Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients. Transl Psychiatry. 2017;7(5):e1111.","journal-title":"Transl Psychiatry"},{"key":"8026_CR43","doi-asserted-by":"publisher","first-page":"735165","DOI":"10.3389\/fphar.2021.735165","volume":"12","author":"MY Al-Shorbagy","year":"2021","unstructured":"Al-Shorbagy MY, Wadie W, El-Tanbouly DM. Trimetazidine Modulates Mitochondrial Redox Status and Disrupted Glutamate Homeostasis in a Rat Model of Epilepsy. Front Pharmacol. 2021;12:735165.","journal-title":"Front Pharmacol"},{"issue":"2","key":"8026_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1071-3581(98)90195-7","volume":"5","author":"M Ciavolella","year":"1998","unstructured":"Ciavolella M. Acute oral trimetazidine administration increases resting technetium 99m sestamibi uptake in hibernating myocardium. J Nuclear Cardiol. 1998;5(2):128\u201333.","journal-title":"J Nuclear Cardiol"},{"issue":"2","key":"8026_CR45","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jpsychires.2010.05.015","volume":"45","author":"F Kapczinski","year":"2011","unstructured":"Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant\u2019Anna M, Klamt F, Moreira JC, de Bittencourt Pasquali MA, Fries GR, Quevedo J, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45(2):156\u201361.","journal-title":"J Psychiatr Res"},{"issue":"1\u20133","key":"8026_CR46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jad.2007.08.006","volume":"107","author":"S Selek","year":"2008","unstructured":"Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 2008;107(1\u20133):89\u201394.","journal-title":"J Affect Disord"},{"issue":"1","key":"8026_CR47","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pnpbp.2011.12.006","volume":"37","author":"U Banerjee","year":"2012","unstructured":"Banerjee U, Dasgupta A, Rout JK, Singh OP. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):56\u201361.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"8026_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1081\/JDI-120005360","volume":"24","author":"PS Satyanarayana","year":"2002","unstructured":"Satyanarayana PS, Chopra K. Oxidative stress-mediated renal dysfunction by cyclosporine A in rats: attenuation by trimetazidine. Ren Fail. 2002;24(3):259\u201374.","journal-title":"Ren Fail"},{"key":"8026_CR49","doi-asserted-by":"publisher","first-page":"108568","DOI":"10.1016\/j.biopha.2019.01.029","volume":"112","author":"N Amini","year":"2019","unstructured":"Amini N, Sarkaki A, Dianat M, Mard SA, Ahangarpour A, Badavi M. The renoprotective effects of naringin and trimetazidine on renal ischemia\/reperfusion injury in rats through inhibition of apoptosis and downregulation of micoRNA-10a. Biomed Pharmacother. 2019;112:108568.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"8026_CR50","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3109\/0886022X.2014.949765","volume":"36","author":"A Mahfoudh-Boussaid","year":"2014","unstructured":"Mahfoudh-Boussaid A, Hadj Ayed Tka K, Zaouali MA, Rosello-Catafau J, Ben Abdennebi H. Effects of trimetazidine on the Akt\/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail. 2014;36(9):1436\u201342.","journal-title":"Ren Fail"},{"key":"8026_CR51","doi-asserted-by":"publisher","first-page":"100108","DOI":"10.1016\/j.crphar.2022.100108","volume":"3","author":"V Dhote","year":"2022","unstructured":"Dhote V, Mandloi AS, Singour PK, Kawadkar M, Ganeshpurkar A, Jadhav MP. Neuroprotective effects of combined trimetazidine and progesterone on cerebral reperfusion injury. Curr Res Pharmacol Drug Discov. 2022;3:100108.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"8026_CR52","unstructured":"Hassanzadeh G, Hosseini A, Pasbakhsh P, Akbari M, Ghaffarpour M, Takzare N, Zahmatkesh M. Trimetazidine prevents oxidative changes induced in a rat model of sporadic type of Alzheimer\u2019s disease. Acta Medica Iranica. 2015:17\u201324."},{"issue":"2","key":"8026_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FJC.0000000000000396","volume":"68","author":"L Shao","year":"2016","unstructured":"Shao L, Ma A, Figtree G, Zhang P. Combination Therapy With Coenzyme Q10 and Trimetazidine in Patients With Acute Viral Myocarditis. J Cardiovasc Pharmacol. 2016;68(2):150\u20134.","journal-title":"J Cardiovasc Pharmacol"},{"key":"8026_CR54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jad.2014.05.009","volume":"166","author":"YM Bai","year":"2014","unstructured":"Bai YM, Su TP, Tsai SJ, Wen-Fei C, Li CT, Pei-Chi T, Mu-Hong C. Comparison of inflammatory cytokine levels among type I\/type II and manic\/hypomanic\/euthymic\/depressive states of bipolar disorder. J Affect Disord. 2014;166:187\u201392.","journal-title":"J Affect Disord"},{"issue":"3","key":"8026_CR55","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1192\/bjp.2018.144","volume":"213","author":"T Rowland","year":"2018","unstructured":"Rowland T, Perry BI, Upthegrove R, Barnes N, Chatterjee J, Gallacher D, Marwaha S. Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses. Br J Psychiatry. 2018;213(3):514\u201325.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"8026_CR56","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1159\/000478067","volume":"42","author":"Q Su","year":"2017","unstructured":"Su Q, Li L, Zhao J, Sun Y, Yang H. Effects of Trimetazidine on PDCD4\/NF-kappaB\/TNF-alpha Pathway in Coronary Microembolization. Cell Physiol Biochem. 2017;42(2):753\u201360.","journal-title":"Cell Physiol Biochem"},{"issue":"20","key":"8026_CR57","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1111\/febs.12484","volume":"280","author":"E Ferraro","year":"2013","unstructured":"Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, Tinari A, Salvatore AM, Malorni W, Berghella L, Rosano G. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. FEBS J. 2013;280(20):5094\u2013108.","journal-title":"FEBS J"},{"issue":"3","key":"8026_CR58","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1620\/tjem.208.203","volume":"208","author":"F Kuralay","year":"2006","unstructured":"Kuralay F, Altekin E, Yazlar AS, Onvural B, Goldeli O. Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine. Tohoku J Exp Med. 2006;208(3):203\u201312.","journal-title":"Tohoku J Exp Med"},{"issue":"2","key":"8026_CR59","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1590\/S0066-782X2012005000066","volume":"99","author":"GF Martins","year":"2012","unstructured":"Martins GF, Siqueira Filho AG, Santos JB, Assuncao CR, Vieira FB, Valencia A, Carvalho KG, Jessen B. Trimetazidine and inflammatory response in coronary artery bypass grafting. Arq Bras Cardiol. 2012;99(2):688\u201396.","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"8026_CR60","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1124\/pr.111.005397","volume":"65","author":"DH Overstreet","year":"2013","unstructured":"Overstreet DH, Wegener G. The flinders sensitive line rat model of depression\u201325 years and still producing. Pharmacol Rev. 2013;65(1):143\u201355.","journal-title":"Pharmacol Rev"},{"key":"8026_CR61","doi-asserted-by":"crossref","unstructured":"Ferrari R, Ford I, Fox K, Challeton JP, Correges A, Tendera M, Widimsk\u00fd P, Danchin N. investigators A: Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2020.","DOI":"10.1016\/S0140-6736(20)31790-6"},{"issue":"4","key":"8026_CR62","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382\u20139.","journal-title":"Br J Psychiatry"},{"key":"8026_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eurpsy.2018.05.006","volume":"53","author":"M Mohebbi","year":"2018","unstructured":"Mohebbi M, Dodd S, Dean OM, Berk M. Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder. Eur Psychiatry. 2018;53:17\u201322.","journal-title":"Eur Psychiatry"},{"issue":"7","key":"8026_CR64","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"8026_CR65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","volume":"73","author":"M Spearing","year":"1997","unstructured":"Spearing M, Post R, Leverich GS, Brandt D, Nolen WA. Modification of the clinical global impressions (CGI) scale for use in bipolar illness. Psychiatry Res. 1997;73:159\u201371.","journal-title":"Psychiatry Res"},{"issue":"5","key":"8026_CR66","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.133.5.429","volume":"133","author":"RC Young","year":"1978","unstructured":"Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429\u201335.","journal-title":"Br J Psychiatry"},{"key":"8026_CR67","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The Assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u20135.","journal-title":"Br J Med Psychol"},{"issue":"4","key":"8026_CR68","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1590\/s0004-2803.201700000-85","volume":"54","author":"D Rossi","year":"2017","unstructured":"Rossi D, Galant LH, Marroni CA. Psychometric Property of Fatigue Severity Scale and Correlation with Depression and Quality of Life in Cirrhotics. Arq Gastroenterol. 2017;54(4):344\u20138.","journal-title":"Arq Gastroenterol"},{"key":"8026_CR69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jad.2020.09.017","volume":"278","author":"E Morton","year":"2021","unstructured":"Morton E, Murray G, Yatham LN, Lam RW, Michalak EE. The Quality of Life in Bipolar Disorder (QoL.BD) questionnaire a decade on - A systematic review of the measurement of condition-specific aspects of quality of life in bipolar-disorder. J Affect Disord. 2021;278:33\u201345.","journal-title":"J Affect Disord"},{"key":"8026_CR70","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2147\/NDT.S209700","volume":"15","author":"J Madera","year":"2019","unstructured":"Madera J, Such P, Zhang P, Baker RA, Grande I. Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment. Neuropsychiatr Dis Treat. 2019;15:2325\u201338.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"8026_CR71","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1017\/S0033291799008570","volume":"29","author":"AC Leon","year":"1999","unstructured":"Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB. The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med. 1999;29(4):869\u201378.","journal-title":"Psychol Med"},{"issue":"2","key":"8026_CR72","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","volume":"165","author":"RS Kern","year":"2008","unstructured":"Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214\u201320.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"8026_CR73","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1017\/S1355617704102191","volume":"10","author":"DC Delis","year":"2004","unstructured":"Delis DC, Kramer JH, Kaplan E, Holdnack J. Reliability and validity of the Delis-Kaplan Executive Function System: an update. J Int Neuropsychol Soc. 2004;10(2):301\u20133.","journal-title":"J Int Neuropsychol Soc"},{"key":"8026_CR74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1471-2458-14-115","volume":"14","author":"CY Noben","year":"2014","unstructured":"Noben CY, Evers SM, Nijhuis FJ, de Rijk AE. Quality appraisal of generic self-reported instruments measuring health-related productivity changes: a systematic review. BMC Public Health. 2014;14:115.","journal-title":"BMC Public Health"},{"issue":"5","key":"8026_CR75","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353\u201365.","journal-title":"PharmacoEconomics"},{"issue":"7","key":"8026_CR76","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s11136-006-0059-z","volume":"15","author":"H Hayhurst","year":"2006","unstructured":"Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res. 2006;15(7):1271\u201380.","journal-title":"Qual Life Res"},{"issue":"3","key":"8026_CR77","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"issue":"4","key":"8026_CR78","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/13651500310002986","volume":"7","author":"C Hawley","year":"2003","unstructured":"Hawley C, Fineberg N, Roberts A, Baldwin D, Sahadevan A, Sharman V. The use of the Simpson Angus Scale for the assessment of movement disorder: A training guide. Int J Psychiatry Clin Pract. 2003;7(4):349\u20132257.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"8026_CR79","volume-title":"Structured clinical interview for DSM-5 disorders\u2013research version (SCID-5-RV)","author":"MB First","year":"2014","unstructured":"First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 disorders\u2013research version (SCID-5-RV). Arlington: American Psychiatric Assocation; 2014."},{"key":"8026_CR80","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-244X-10-10","volume":"10","author":"M Hesse","year":"2010","unstructured":"Hesse M, Moran P. Screening for personality disorder with the Standardised Assessment of Personality: Abbreviated Scale (SAPAS): further evidence of concurrent validity. BMC Psychiatry. 2010;10:10.","journal-title":"BMC Psychiatry"},{"key":"8026_CR81","doi-asserted-by":"publisher","first-page":"101005","DOI":"10.1016\/j.eclinm.2021.101005","volume":"38","author":"R McKetin","year":"2021","unstructured":"McKetin R, Dean OM, Turner A, Kelly PJ, Quinn B, Lubman DI, Dietze P, Carter G, Higgs P, Sinclair B, et al. N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. EClinicalMedicine. 2021;38:101005.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"8026_CR82","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0706743720982437","volume":"66","author":"A Turner","year":"2021","unstructured":"Turner A, Baker A, Dean OM, Walker AJ, Dodd S, Cotton SM, Scott JG, Kavanagh BE, Ashton MM, Brown E, et al. Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Pericarpe d\u2019appoint Garcinia mangostana Linn (mangoustan) pour la schizophrenie: un essai d\u2019efficacite de 24 semaines, a double insu, randomise et controle par placebo. Can J Psychiatry. 2021;66(4):354\u201366.","journal-title":"Can J Psychiatry"},{"key":"8026_CR83","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0165-0327(00)00242-1","volume":"64","author":"P Svanborg","year":"2001","unstructured":"Svanborg P, Asberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating. J Affect Disord. 2001;64:203\u201316.","journal-title":"J Affect Disord"},{"key":"8026_CR84","doi-asserted-by":"publisher","first-page":"107075","DOI":"10.1016\/j.addbeh.2021.107075","volume":"123","author":"AA Guerin","year":"2021","unstructured":"Guerin AA, Drummond KD, Bonomo Y, Lawrence AJ, Rossell SL, Kim JH. Assessing methamphetamine-related cue reactivity in people with methamphetamine use disorder relative to controls. Addict Behav. 2021;123:107075.","journal-title":"Addict Behav"},{"issue":"4","key":"8026_CR85","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/da.22297","volume":"32","author":"M Russo","year":"2015","unstructured":"Russo M, Mahon K, Burdick KE. Measuring cognitive function in MDD: emerging assessment tools. Depress Anxiety. 2015;32(4):262\u20139.","journal-title":"Depress Anxiety"},{"issue":"2","key":"8026_CR86","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"},{"issue":"6","key":"8026_CR87","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jpsychires.2004.03.007","volume":"38","author":"M Zimmerman","year":"2004","unstructured":"Zimmerman M, Posternak MA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res. 2004;38(6):577\u201382.","journal-title":"J Psychiatr Res"},{"issue":"6","key":"8026_CR88","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1192\/bjp.bp.111.093336","volume":"199","author":"ME Thase","year":"2011","unstructured":"Thase ME, Larsen KG, Kennedy SH. Assessing the \u2018true\u2019 effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry. 2011;199(6):501\u20137.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"8026_CR89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12916-019-1475-6","volume":"18","author":"M Berk","year":"2020","unstructured":"Berk M, Mohebbi M, Dean OM, Cotton SM, Chanen AM, Dodd S, Ratheesh A, Amminger GP, Phelan M, Weller A, et al. Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin. BMC Med. 2020;18(1):16\u201312.","journal-title":"BMC Med"},{"key":"8026_CR90","doi-asserted-by":"crossref","unstructured":"Berk M, Agustini B, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, Fitzgerald SM, Lockery JE, Wolfe R, et al. Effects of aspirin on the long-term management of depression in older people: a double-blind randomised placebo-controlled trial. Mol Psychiatry. 2021.","DOI":"10.1038\/s41380-021-01020-5"},{"issue":"10","key":"8026_CR91","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/jamapsychiatry.2020.1214","volume":"77","author":"M Berk","year":"2020","unstructured":"Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, Fitzgerald S, Lockery JE, Wolfe R, Mohebbi M, et al. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(10):1012\u201320.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"8026_CR92","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-017-0791-y","volume":"15","author":"FN Jacka","year":"2017","unstructured":"Jacka FN, O\u2019Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, Castle D, Dash S, Mihalopoulos C, Chatterton ML, et al. A randomised controlled trial of dietary improvement for adults with major depression (the \u2018SMILES\u2019 trial). BMC Med. 2017;15(1):23.","journal-title":"BMC Med"},{"key":"8026_CR93","doi-asserted-by":"crossref","unstructured":"Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, Goldstein BI, Harvey A, Laghrissi-Thode F, Leboyer M, et al. Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder. Ann N Y Acad Sci. 2011;1242:1\u201325.","DOI":"10.1111\/j.1749-6632.2011.06336.x"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08026-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:06:28Z","timestamp":1778720788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08026-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8026"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08026-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. The TIDE trial protocol is approved by the Deakin University Human Research Ethics Committee (DUHREC project ID: JK02900). The trial has commenced recruitment at NIMHANS (NIMHANS Institute Ethics Committee approved project ID: NIMHANS\/EC (BEH.SC.DIV.)\/2025) and CIP (CIP Institute Ethics Committee approved project ID: IEC\/CIP\/2022-23\/171) but not in any other sites. Prior to commencing any trial-related activity, written informed consent is obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors meet standard authorship criteria and approved this submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}